Hemispherian Oncology
Innovative therapeutics for aggressive brain tumors
Tell me more


Our mission is to improve the lives of adults and children afflicted with an agressive brain tumor.

  • Brain Cancer and Treatments

    Glioblastoma multiforme is the most prevalent and aggressive malignant tumor of the central nervous system. Currently available treatments do not have the desired impact and only marginally improve life expectancy. Glioblastoma multiforme has one of the highest unmet needs in oncology.

  • Our Solution

    We have identified two compounds that specifically and selectively kill glioblastoma multiforme cells. Models have shown that tumors are regressing to the point where there is no tumor mass identifiable. These drugs are well tolerated in animal models and are expected to be well tolerated in humans.

  • The Market

    In 2014, a combined 84,704 cases of glioblastoma multiform were diagnosed in France, Germany, Italy, Spain, UK, US and Japan. Glioblastoma multiforme is the 17th most common cancer and the second most common cancer in children. The majority of glioblastoma multiforme tumors are resistant to the frontline chemotherapeutic drug. There is no standard second line treatment.

  • Our Partners

    We are collaborating with neurosurgeons, chemists, and international contract research organizations.

  • The next Step

    We are actively looking for partners and investors. If you are interested in working with us, or if you would like more information about our cause please contact us below.

  • Be partof ourquest!


The latest information about our work

Our team

We are a company of scientists, engineers and entrepreneurs working together for many years.

Dr. Adam Robertson

Dr. Adam Robertson

Adam is a biochemist and currently a group leader at Oslo University Hospital.

Terezia Prikrylova

Terezia Prikrylova

Terezia is a biologist and is also a co-inventor of the drugs developed by Hemispherian.

Anett Monika Diaz

Anett Monika Diaz

Anett is an Industrial Engineer and spent most of her career in Corporate Sales and Marketing. She supports in questions of Business Development in Hemispherian.

Zeno Albisser

Zeno Albisser

Zeno is a computer scientist and entrepreneur. He is the founder and CEO of Hemispherian.

Nils Anders Labba

Nils Anders Labba

Nils Anders is our in-house specialist for neurochemistry and neurotoxicology questions.

Kristin Marie Dahlgren

Kristin Marie Dahlgren

Kristin is a toxicologist and is helping us to assess the safety of our compounds.

Contact us

Postal Address

Hemispherian Oncology
Gaustadalléen 21
NO-0349 Oslo

Phone & E-Mail

+47 406 03 455